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THE INFLUENCE OVER THE LONG-TERM PROGNOSIS OF 
BCG THERAPY AND THE SURGICAL TREATMENT IN 
SUPERFICIAL BLADDER CANCER TREATMENT 
Shin HIGASHI， Yoshiyuki MATSUI， Takeshi TAKAHASHI， Hiroyuki NISHIYAMA， 
Noriyuki 1T0， Shingo YAMAMOTO， Toshiyuki KAMOTO and Osamu OGAWA 
The Department ぜかolofJらめotoUniversity Graduate School 01 Medicine 
From the view point that total cystectomy is important in treatment of carcinoma in situ (CIS) of 
the bladder， we reviewed the cases showing resistance to bacillus Calmette-Guerin (BCG) among 42 
CIS treated with intravesical BCG. Twenty-six cases were cured by BCG treatment. Twelve total 
cystectomies were done in 16 cases of BCG-resistant CIS of the bladder. Four died with urethral 
invasion or upper urinary tract recurrence. There was invasion into the prostate in 3 cases. The 
development of CIS to the upper urinary tract and the prostatic urethra is not rare and this has an 
infiuence on the prognosis. In bladder CIS treatment， the inspection to see extravesical progression is 
necessary. It is important not to delay the radical cystectomy. 
(Hinyokika Kiyo 51 : 529-531， 2005) 














































530 泌尿紀要 51巻 8号 2005年
BCG therapy for ClS 
42 
Fig. 1. The proximity effect after treatment in the 
自rsttime by the BCG to CIS. 
Fig. 2. The operation and the emerged upper 
urinary tract tumors of 16 CIS which 
resisted BCG. The number which 
showed no response to initial BCG treat-











































































東，ほか:腸枕上皮内癌 BCG抵抗性 531 
たとしている7) また， Lorenzoらは BCG治療既往
のある24例の Ta/Tl勝脱癌症例への追加治療として
9例で腸脱全摘を行い，尿管で6例，前立腺で4例に





















をせ± 吾.oドー ー耶ロ 開聞
1. CISを合併する表在性腸脱癌に対し BCG腸脱
内注入を行った42例について検討を行った.
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